← Back to Clinical Trials
Recruiting NCT07704489

NCT07704489 San Raffaele Registry on Liver Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07704489
Status Recruiting
Phase
Sponsor IRCCS San Raffaele
Condition Liver and Intrahepatic Biliary Tract Cancer
Study Type OBSERVATIONAL
Enrollment 4,000 participants
Start Date 2021-10-20
Primary Completion 2050-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 4,000 participants in total. It began in 2021-10-20 with a primary completion date of 2050-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a Retrospective and Prospective Observational Single-Center Study. The purpose is to collect all data to generate a registry of primary liver cancer (hepatocellular carcinoma and biliary tract carcinoma) of patients accessing to San Raffaele Hospital. An additional purpose is to identify novel biomarkers to better manage primary liver cancer patients, for whom additional biological samples will be collected. A total of 4000 patients will be enrolled; for the prospective cohort: from protocol approval to the achievement of the last planned patients in the prospective cohort (2000 patients). The retrospective cohort will start from the year 2000. Patients will be followed for 5 years of follow-up.

Eligibility Criteria

Inclusion Criteria: 1. Participant is willing and able to give informed consent for participation in the study. However, concerning the retrospective cohort, the large sample sizes needed and considering that the disease involved in this study affects elderly subjects with co-morbidities and presents a significant mortality rate based on the stage of the disease, deceased and untraceable patients will also be included. 2. ≥18 years of age. 3. Patients diagnosed with any subtype of biliary tract cancer (i.e. iCCA, pCCA, dCCA or GBC) at every stage and with all therapeutic indications. 4. Patients diagnosed with hepatocellular carcinoma at every stage and treated with all therapeutic options. Exclusion Criteria: 1\. Patients without diagnosis of hepatocellular carcinoma or biliary tract cancer (BTC).

Contact & Investigator

Central Contact

Andrea Casadei Gardini, Medical Oncologist

✉ CasadeiGardini.Andrea@hsr.it

📞 +390226437627

Frequently Asked Questions

Who can join the NCT07704489 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Liver and Intrahepatic Biliary Tract Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07704489 currently recruiting?

Yes, NCT07704489 is actively recruiting participants. Contact the research team at CasadeiGardini.Andrea@hsr.it for enrollment information.

Where is the NCT07704489 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT07704489 clinical trial?

NCT07704489 is sponsored by IRCCS San Raffaele. The trial plans to enroll 4,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology